Inventor · disambiguated record
Qinda Ye
Also filed as: YE QINDA
22 granted patents·8 pending applications·204 citations·filing 2017–2025
95Inventor score
Files withINCYTE CORP30
Top patents by PatentIndex Score
30 records- 0197US11542265B2Pyrazolopyrimidine compounds and uses thereofINCYTE CORP·Filed 2021·Granted Jan 3, 2023·8 cites·43 claims
- 0297US11492354B2Indazole compounds and uses thereofINCYTE CORP·Filed 2020·Granted Nov 8, 2022·8 cites·71 claims
- 0397US11242343B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2020·Granted Feb 8, 2022·12 cites·27 claims
- 0497US10934288B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2019·Granted Mar 2, 2021·13 cites·8 claims
- 0597US10745388B2Indazole compounds and uses thereofINCYTE CORP·Filed 2019·Granted Aug 18, 2020·24 cites·22 claims
- 0697US10435405B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2018·Granted Oct 8, 2019·23 cites·16 claims
- 0796US11447494B2Tricyclic amine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Sep 20, 2022·8 cites·41 claims
- 0896US11427567B2Imidazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Aug 30, 2022·8 cites·22 claims
- 0996US10752635B2Indazole compounds and uses thereofINCYTE CORP·Filed 2019·Granted Aug 25, 2020·16 cites·67 claims
- 1095US11891388B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2021·Granted Feb 6, 2024·3 cites·30 claims
- 1195US11440914B2Tricyclic amine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2020·Granted Sep 13, 2022·7 cites·37 claims
- 1295US11406624B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2019·Granted Aug 9, 2022·9 cites·16 claims
- 1395US10899755B2Benzothiazole compounds and uses thereofINCYTE CORP·Filed 2019·Granted Jan 26, 2021·15 cites·39 claims
- 1494US11866426B2Benzothiazole compounds and uses thereofINCYTE CORP·Filed 2020·Granted Jan 9, 2024·3 cites·41 claims
- 1594US10280164B2Pyrazolopyridone compounds and uses thereofINCYTE CORP·Filed 2017·Granted May 7, 2019·24 cites·38 claims
- 1693US12384778B2Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2023·Granted Aug 12, 2025·1 cites·49 claims
- 1792US11299473B2Benzimidazole and indole compounds and uses thereofINCYTE CORP·Filed 2019·Granted Apr 12, 2022·10 cites·56 claims
- 1892US11014929B2Pyrazolopyrimidine compounds and uses thereofINCYTE CORP·Filed 2019·Granted May 25, 2021·12 cites·54 claims
- 1980US11939328B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2022·Granted Mar 26, 2024·0 cites·35 claims
- 2079US12378243B2Quinoline compounds as inhibitors of KRASINCYTE CORP·Filed 2024·Granted Aug 5, 2025·0 cites·34 claims
- 2178US2025243183A1Imidazolyl pyrimidinylamine compounds as cdk2 inhibitorsINCYTE CORP·Filed 2025·Application pending·0 cites
- 2277US12466815B2Carboxamide compounds and uses thereofINCYTE CORP·Filed 2023·Granted Nov 11, 2025·0 cites·66 claims
- 2375US12312331B2Imidazolyl pyrimidinylamine compounds as CDK2 inhibitorsINCYTE CORP·Filed 2022·Granted May 27, 2025·0 cites·35 claims
- 2474US2025368641A1Quinoline compounds as inhibitors of krasINCYTE CORP·Filed 2025·Application pending·0 cites
- 2565US2019315743A1Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2019·Application pending·0 cites
- 2660US2024101557A1Fused tricyclic compounds as inhibitors of kras g12v mutantsINCYTE CORP·Filed 2023·Application pending·0 cites
- 2760US2018072718A1Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2017·Application pending·0 cites
- 2857US2023226040A1Combination therapy comprising an fgfr inhibitor and a kras inhibitorINCYTE CORP·Filed 2022·Application pending·0 cites
- 2953US2018072741A1Pyrazolopyrimidine compounds and uses thereofINCYTE CORP·Filed 2017·Application pending·0 cites
- 3049US2018228786A1Pyrazolopyridine compounds and uses thereofINCYTE CORP·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Qinda Ye files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →